AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS (AI-ECG-TIMI)
Artificial Intelligence-Powered Electrocardiogram Detecting Culprit Vessel Blood Flow Abnormality in Acute Coronary Syndromes
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Timea Kisova, MD
- Phone Number: +421901766801
- Email: tkisova@powerfulmedical.com
Study Locations
-
-
-
Bruck an der Mur, Austria
- LKH Hochsteiermark, Standort Bruck
-
Graz, Austria
- Medical University of Graz
-
Graz, Austria, 8020
- LKH II Standort West
-
-
-
-
-
Aalst, Belgium
- OLV Aalst
-
Bruges, Belgium
- AZ Sint Jan
-
Hasselt, Belgium
- Jessa Ziekenhuis
-
-
-
-
-
Chieti, Italy
- University Hospital D'Annunzio Chieti
-
Rome, Italy
- San Pietro Hospital
-
Rome, Italy
- Sant´Andrea Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with acute coronary syndromes undergoing invasive coronary angiography as clinically indicated.
- Availability of a standard 12-lead ECG performed at invasive coronary angiogram before percutaneous coronary intervention (maximum within 15 min before vascular access).
- Age ≥18 years.
Exclusion Criteria:
- Individuals presenting for a non-emergent (elective) cardiac catheterization.
- Individuals presenting with chronic coronary syndrome (CCS) or stable angina symptoms.
- Individuals without symptoms suspicious for acute coronary syndromes.
- Individuals with contraindications for cardiac catheterization.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic Accuracy of the AI-ECG TIMI AI Model
Time Frame: Index hospitalization (assessed up to 5 days)
|
The primary endpoint is the AI-ECG TIMI model's ability to identify patients with actively occluded (TIMI 0-1) at the time of invasive coronary angiography using only single-standard 12-lead ECGs assessed by accuracy, sensitivity, specificity, positive, negative predictive values and F1 scores.
|
Index hospitalization (assessed up to 5 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subgroup Performance
Time Frame: Index hospitalization (assessed up to 5 days)
|
AI-ECG TIMI AI Model's performance across subgroups
|
Index hospitalization (assessed up to 5 days)
|
|
Correlate established definitions of occlusion myocardial infarction (OMI) to myocardial perfusion status
Time Frame: Index hospitalization (assessed up to 5 days)
|
2. OMI definitions using routine angiographic and laboratory parameters will be correlated to abnormal myocardial perfusion using correlation coefficients.
|
Index hospitalization (assessed up to 5 days)
|
|
ECG prediction of mechanical reperfusion
Time Frame: Index hospitalization (assessed up to 5 days)
|
a. Correlation of AI-ECG TIMI model's raw numeric predictions (between 0 and 1) with myocardial perfusion grading post PCI.
|
Index hospitalization (assessed up to 5 days)
|
|
Assessment of expert ECG interpretation blinded to all clinical information
Time Frame: Index hospitalization (assessed up to 5 days)
|
|
Index hospitalization (assessed up to 5 days)
|
|
STEMI-equivalent ECG patterns
Time Frame: Index hospitalization (assessed up to 5 days)
|
a. Prevalence of STEMI equivalent ECG patterns and their correlation to TIMI flow grade at angiography.
|
Index hospitalization (assessed up to 5 days)
|
|
Subgroup analysis of NSTEMI-OMI patients
Time Frame: Index hospitalization (assessed up to 5 days)
|
9. NSTEMI-OMI stratified according to immediate (<2h) vs. SoC (>2h) invasive management, median: i. Peak troponin (maximum rise before fall) ii.
Median LVEF at discharge iii.
Length of hospital stay iv.
Length of cardiac care unit (CCU) or intensive care unit (ICU) stay v. Presence of life-threatening arrhythmias
|
Index hospitalization (assessed up to 5 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Robert Herman, MD, PhD, Powerful Medical
- Study Chair: Emanuele Barbato, MD, PhD, University of Roma La Sapienza
- Study Chair: Jozef Bartunek, MD, PhD, Azorg Hospital, Aalst
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Infarction
- Necrosis
- Coronary Disease
- Myocardial Ischemia
- Ischemia
- Chest Pain
- Angina Pectoris
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- ST Elevation Myocardial Infarction
- Non-ST Elevated Myocardial Infarction
- Myocardial Infarction
- Acute Coronary Syndrome
- Angina, Unstable
- Coronary Occlusion
Other Study ID Numbers
Other Study ID Numbers
- AI-ECG-TIMI_v1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.